Oppenheimer analyst Jay Olson raised the firm’s price target on Biogen to $325 from $310 and keeps an Outperform rating on the shares after the company provided Q1 financial results. The firm notes the company focused on a refreshed business plan with impressive progress, including two new product launches that are underappreciated in the near-term and long-term; R&D prioritization in areas of clear leadership and promising new opportunities; termination of R&D projects lacking confidence and/or deemed too risky; cost management to fund prioritized investments near term and operating margin expansion longer term; organizational progress with new heads of BD and IR while a new R&D head is expected by end of summer; several successful collaborations support Biogen’s position as a partner of choice; and financial firepower for additional BD.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BIIB:
- Biogen price target lowered to $302 from $307 at Barclays
- FDA approves Ionis Pharma/Biogen’s QALSODY as first treatment in ALS
- Biogen price target raised to $371 from $349 at Morgan Stanley
- FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
- Biogen confirms FDA grants accelerated approval for Qalsody